Takeda Play

Filtrer videoene per terapiområde

Artikkel

Sikkerhet

The ADZYNMA safety profile was demonstrated in a Phase 3, open-label, crossover trial (NCT03393975), adverse events occurred in 71% of the patients with ADZYNMA.

Mer

Artikkel

Programoversikt

The ADZYNMA clinical development programme included a pivotal, randomised, controlled Phase 3 study, the first of its kind in cTTP patients.

Mer
Subscribe to